共 67 条
[1]
[Anonymous], 2013, Reflection paper on management of clinical risks deriving from insertional mutagenesis Reflection paper on management of clinical risks deriving from insertional mutagenesis
[2]
[Anonymous], 1997, ICH HARM TRIP GUID D
[3]
[Anonymous], Replacement of Annex 1 of WHO Technical Report Series, V878
[4]
[Anonymous], 2006, Commission Directive 2006/17/EC regarding certain technical requirements for the donation, procurement and testing of human tissues and cells
[5]
[Anonymous], 1999, ICH Topic Q 6 B. Specifications: Test Procedures and Acceptance Criteria for
[6]
[Anonymous], 2004, Directive 2004/23/EC-European tissues and cells directive
[7]
[Anonymous], 1997, ICH Topic Q 5 A (R1) Quality of biotechnological products: Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin step 5 note for guidance on quality of biotechnological products: Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin
[8]
[Anonymous], 1996, ICH Topic Q 5 C Quality of biotechnological products: Stability testing of biotechnological/biological products step 5 note for guidance on quality of biotechnolo-gical products: Stability testing of biotechnological/biological products final approval by CPMP December 1995 proposed date for coming into operation
[9]
Babu Sahana Suresh, 2023, Biotechnology Reports, V37, pe00784, DOI 10.1016/j.btre.2023.e00784
[10]
cGMP-Manufactured Human Induced Pluripotent Stem Cells Are Available for Pre-clinical and Clinical Applications
[J].
STEM CELL REPORTS,
2015, 5 (04)
:647-659